 DEVON, Pa., Nov. 09, 2020 GLOBE NEWSWIRE -- Zynerba Pharmaceuticals, Inc. NASDAQ:ZYNE, the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2020, and provided an overview of recent operational highlights. 